Monopar Therapeutics (MNPR) Operating Income: 2016-2019
Historic Operating Income for Monopar Therapeutics (MNPR) over the last 4 years, with Dec 2019 value amounting to -$4.3 million.
- Monopar Therapeutics' Operating Income fell 32.23% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.3 million, marking a year-over-year decrease of 36.88%. This contributed to the annual value of -$4.3 million for FY2019, which is 29.80% down from last year.
- Per Monopar Therapeutics' latest filing, its Operating Income stood at -$4.3 million for FY2019, which was down 29.80% from -$3.3 million recorded in FY2018.
- Over the past 5 years, Monopar Therapeutics' Operating Income peaked at -$1.2 million during FY2016, and registered a low of -$16.6 million during FY2017.
- In the last 3 years, Monopar Therapeutics' Operating Income had a median value of -$4.3 million in 2019 and averaged -$8.1 million.
- As far as peak fluctuations go, Monopar Therapeutics' Operating Income tumbled by 1,291.91% in 2017, and later spiked by 79.94% in 2018.
- Over the past 4 years, Monopar Therapeutics' Operating Income (Yearly) stood at -$1.2 million in 2016, then tumbled by 1,291.91% to -$16.6 million in 2017, then soared by 79.94% to -$3.3 million in 2018, then declined by 29.80% to -$4.3 million in 2019.